Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

BACKGROUND: We report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) from an ongoing phase 3 trial. METHODS: Adults at increased risk of SARS-CoV-2 infection were randomized (2:1), stratified by age, to receive 2 doses of AZD1222 or placebo. The primary efficacy end point...

Descripción completa

Detalles Bibliográficos
Autores principales: Sobieszczyk, Magdalena E., Maaske, Jill, Falsey, Ann R., Sproule, Stephanie, Robb, Merlin L., Frenck, Robert W., Tieu, Hong-Van, Mayer, Kenneth H., Corey, Lawrence, Neuzil, Kathleen M., Tong, Tina, Brewinski Isaacs, Margaret, Janes, Holly, Bansal, Himanshu, Edwards, Lindsay M., Green, Justin A., Kelly, Elizabeth J., Shoemaker, Kathryn, Takas, Therese, White, Tom, Bhuyan, Prakash, Villafana, Tonya, Hirsch, and Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479753/
https://www.ncbi.nlm.nih.gov/pubmed/36106642
http://dx.doi.org/10.1172/JCI160565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479753/
https://www.ncbi.nlm.nih.gov/pubmed/36106642
http://dx.doi.org/10.1172/JCI160565

Ejemplares similares